JP2016525502A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525502A5
JP2016525502A5 JP2016519574A JP2016519574A JP2016525502A5 JP 2016525502 A5 JP2016525502 A5 JP 2016525502A5 JP 2016519574 A JP2016519574 A JP 2016519574A JP 2016519574 A JP2016519574 A JP 2016519574A JP 2016525502 A5 JP2016525502 A5 JP 2016525502A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016519574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525502A (ja
JP6446443B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2013/055203 external-priority patent/WO2014028777A2/en
Application filed filed Critical
Priority claimed from PCT/US2014/041553 external-priority patent/WO2014200921A1/en
Publication of JP2016525502A publication Critical patent/JP2016525502A/ja
Publication of JP2016525502A5 publication Critical patent/JP2016525502A5/ja
Application granted granted Critical
Publication of JP6446443B2 publication Critical patent/JP6446443B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016519574A 2013-06-10 2014-06-09 タウオパチーの処置方法 Expired - Fee Related JP6446443B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361833355P 2013-06-10 2013-06-10
US61/833,355 2013-06-10
PCT/US2013/055203 WO2014028777A2 (en) 2012-08-16 2013-08-15 Methods of treating a tauopathy
USPCT/US2013/055203 2013-08-15
US14/092,539 US8926974B2 (en) 2012-08-16 2013-11-27 Methods of treating a tauopathy
US14/092,539 2013-11-27
PCT/US2014/041553 WO2014200921A1 (en) 2013-06-10 2014-06-09 Methods of treating a tauopathy

Publications (3)

Publication Number Publication Date
JP2016525502A JP2016525502A (ja) 2016-08-25
JP2016525502A5 true JP2016525502A5 (enExample) 2017-06-29
JP6446443B2 JP6446443B2 (ja) 2018-12-26

Family

ID=52022687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519574A Expired - Fee Related JP6446443B2 (ja) 2013-06-10 2014-06-09 タウオパチーの処置方法

Country Status (19)

Country Link
EP (2) EP3760228A1 (enExample)
JP (1) JP6446443B2 (enExample)
CN (1) CN105339002B (enExample)
BR (1) BR112015030356A2 (enExample)
CA (2) CA3173775A1 (enExample)
CY (1) CY1123672T1 (enExample)
DK (1) DK3007726T3 (enExample)
EA (1) EA039554B1 (enExample)
ES (1) ES2800827T3 (enExample)
HR (1) HRP20201064T1 (enExample)
HU (1) HUE050485T2 (enExample)
LT (1) LT3007726T (enExample)
MX (2) MX370723B (enExample)
PL (1) PL3007726T3 (enExample)
PT (1) PT3007726T (enExample)
RS (1) RS60883B1 (enExample)
SI (1) SI3007726T1 (enExample)
SM (1) SMT202000401T1 (enExample)
WO (1) WO2014200921A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン,インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
UA126272C2 (uk) * 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
EP3496750A2 (en) 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
FR3058143B1 (fr) * 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CN110770253A (zh) * 2017-06-16 2020-02-07 百时美施贵宝公司 用于治疗tau蛋白病的组合物和方法
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
CN112543648A (zh) 2018-07-31 2021-03-23 伊莱利利公司 组合疗法
JP2022043373A (ja) * 2018-12-28 2022-03-16 国立大学法人京都大学 大脳皮質細胞からのl1cam陽性細胞の取得およびその細胞製剤としての使用
EP3947446A1 (en) * 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US6010913A (en) 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
DE69526377T2 (de) 1994-12-09 2002-11-07 Microscience Ltd Virulenzgene in der VGC2-Region von Salmonella
US5939045A (en) 1994-12-22 1999-08-17 Nissan Chemical Industries, Ltd. Organic bismuth derivatives for X-ray imaging
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP2001525470A (ja) 1997-12-12 2001-12-11 マクロメド・インコーポレーテッド タンパク修飾のためのヘテロ官能化星形ポリ(エチレングリコール)
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
BR0107851A (pt) 2000-01-24 2002-10-29 Innogenetics Nv Diagnose de tauopatia
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
MXPA04002661A (es) 2001-09-21 2004-11-22 Sanofi Aventis Derivados de pirimidona 4, 3-sustituida.
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
US9605054B2 (en) * 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
SG189174A1 (en) * 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
US8703137B2 (en) * 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
DK2885010T3 (da) * 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US20140056901A1 (en) * 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies

Similar Documents

Publication Publication Date Title
HRP20201064T1 (hr) Postupci liječenja tauopatije
US12540175B2 (en) Anti-ApoE antibodies
León et al. Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms
JP2015530971A5 (enExample)
JP2018502840A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2023520821A (ja) 血液脳関門送達のための組成物および方法
JP2017530722A5 (enExample)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
JP2015532592A5 (enExample)
RU2015143886A (ru) Антитела к тау и способы применения
AR109298A1 (es) Anticuerpos multiepitópicos y multivalentes que tienen actividad agonista y métodos de uso
JP2018503357A5 (enExample)
RU2018135371A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
WO2015200806A3 (en) Humanized anti-tau antibodies
JP2016529229A5 (enExample)
JP2019527194A5 (enExample)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2015533795A5 (enExample)
JP2011046732A5 (enExample)
TW201802117A (zh) PDGF受體β結合多肽
JP2015504421A5 (enExample)
JP2015503909A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения